Publications by authors named "Mads D M Engelmann"

Claim this Profile
I
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.
Johannes F E Mann, Nikolaus Marx, John E Deanfield, Scott S Emerson, Silvio E Inzucchi, Mads D M Engelmann

Diabetes Care· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
Marianna Fontana, Pablo Garcia-Pavia, Martha Grogan, Sanjiv J Shah, Mads D M Engelmann

Circulation· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
Nikolaus Marx, John E Deanfield, Johannes F E Mann, Rosario Arechavaleta, Stephen C Bain, Mads D M Engelmann

Circulation· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
Darren K McGuire, Nikolaus Marx, Sharon L Mulvagh, John E Deanfield, Silvio E Inzucchi, Mads D M Engelmann

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
Darren K McGuire, Rodica P Busui, John Deanfield, Silvio E Inzucchi, Johannes F E Mann, Mads D M Engelmann

Diabetes Obes Metab· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24-Hour Holter Electrocardiogram Recordings.
Dorthe Skovgaard, Poul-Martin Haahr, Robert Lester, Katherine Clark, Sabina Paglialunga, Mads D M Engelmann

J Clin Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Paul M Ridker, Matt Devalaraja, Florian M M Baeres, Mads D M Engelmann, G Kees Hovingh

Lancet· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammation in the genesis and perpetuation of atrial fibrillation.
Mads D M Engelmann, Jesper Hastrup Svendsen

Eur Heart J· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation.
Mads D M Engelmann, Lea Niemann, Inge-Lis Kanstrup, Knud Skagen, John Godtfredsen

Int J Cardiol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Quality of life of patients given pharmacological treatment for atrial fibrillation].
Mads D M Engelmann, John Godtfredsen

Ugeskr Laeger· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Quality of life of non-pharmacologically treated patients with atrial fibrillation].
Mads D M Engelmann, Steen Michael Pehrson

Ugeskr Laeger· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-lymphocyte subsets, thymic size and breastfeeding in infancy.
Dorthe L Jeppesen, Helle Hasselbalch, Ida M Lisse, Annette K Ersbøll, Mads D M Engelmann

Pediatr Allergy Immunol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in nonpharmacologic treatment of atrial fibrillation.
Mads D M Engelmann, Steen Pehrson

Eur Heart J· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis